The financing has taking a considerable amount of risk off the table for IME - namely liquidity/funding risk.
Alumina Partners (http://www.aluminapartners.com/) clearly likes what IME is working toward and has stepped up to the plate to offer funding support. As I have said before, given the 2017 plans for development and 2018 commercial launch, this company could easily be worth 10x current levels in 12 months.
To Alumina, this is a no brainer. It means no further dilution to private placement raises and they get to partner with Imagin to take the technology across the finish line. Retail investors are fickle and impatient and get distracted by the latest fad sector. It is often difficult to get retail support behind a company like Imagin because it won't generate tons of news flow but when news does come out it will represent major milestones on the path to commercial launch in 2018.
Just look at a sample of investments in the Alumina portfolio below. Recognize any? The structure of the facility is specifically designed for IME to do small draws on the facility as funding is needed. The share price will continue to climb with IRB approval, human trials, FDA review, FDA approval, product miniaturization, commercial launch and Alumina will fund the progress at successively higher conversion prices, thereby minimizing dilution (versus if the full $8M was funded at the current price level).
One thing is for certain, there will no longer be a funding overhang on the stock from this point, so all news will generate new demand and drive the price higher.
News 
Market Data 
Discover 
